Gary M Strauss

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. pmc Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Gary M Strauss
    Tufts Medical Center, Division of Medical Oncology, Tufts NEMC, Boston, MA 02111, USA
    J Clin Oncol 26:5043-51. 2008
  2. doi request reprint The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups
    Michael T Jaklitsch
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 144:33-8. 2012
  3. doi request reprint Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screenin
    Francine L Jacobson
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 144:25-32. 2012
  4. ncbi request reprint Management of early-stage lung cancer: past, present, and future adjuvant trials
    Gary M Strauss
    Lung Cancer Program, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Oncology (Williston Park) 20:1651-63; discussion 1663-4, 1666, 1669-70 passim. 2006
  5. pmc Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study
    Christina S Baik
    Division of Hematology Oncology, Tufts Medical Center, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 19:2525-33. 2010
  6. ncbi request reprint Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances
    Gary M Strauss
    Division of Medical Oncology, Comprehensive Cancer Center of Rhode Island, Rhode Island Hospital, Brown Medical School, 593 Eddy Street, Providence, RI 02903, USA
    Hematol Oncol Clin North Am 19:263-81, vi. 2005
  7. pmc Differences in clinical trial patient attributes and outcomes according to enrollment setting
    Elizabeth B Lamont
    Dept of Health Care Policy, Harvard Medical School, 180A Longwood Ave, Boston, MA 02115, USA
    J Clin Oncol 28:215-21. 2010
  8. doi request reprint Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study
    Steven W Hwang
    Department of Neurosurgery, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    J Neurooncol 98:77-82. 2010
  9. ncbi request reprint Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference
    Gary M Strauss
    Division of Medical Oncology, Rhode Island Hospital, Brown Medical School, 593 Eddy St, Providence, RI 02903, USA
    Chest 127:1146-51. 2005
  10. ncbi request reprint The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality
    Gary M Strauss
    Division of Hematology Oncology, Roger Williams Medical Center, Providence, RI 02908, USA
    J Clin Oncol 20:1973-83. 2002

Detail Information

Publications10

  1. pmc Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
    Gary M Strauss
    Tufts Medical Center, Division of Medical Oncology, Tufts NEMC, Boston, MA 02111, USA
    J Clin Oncol 26:5043-51. 2008
    ..This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC...
  2. doi request reprint The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups
    Michael T Jaklitsch
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 144:33-8. 2012
    ..Lung cancer is the leading cause of cancer death in North America. Low-dose computed tomography screening can reduce lung cancer-specific mortality by 20%...
  3. doi request reprint Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screenin
    Francine L Jacobson
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Thorac Cardiovasc Surg 144:25-32. 2012
    ..The study objective was to establish The American Association for Thoracic Surgery (AATS) lung cancer screening guidelines for clinical practice...
  4. ncbi request reprint Management of early-stage lung cancer: past, present, and future adjuvant trials
    Gary M Strauss
    Lung Cancer Program, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    Oncology (Williston Park) 20:1651-63; discussion 1663-4, 1666, 1669-70 passim. 2006
    ..It also considers newer approaches to adjuvant therapy, with a particular focus on strategies that incorporate our growing knowledge of molecular medicine and predictive factors to the field of adjuvant chemotherapy of lung cancer...
  5. pmc Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study
    Christina S Baik
    Division of Hematology Oncology, Tufts Medical Center, Boston, Massachusetts, USA
    Cancer Epidemiol Biomarkers Prev 19:2525-33. 2010
    ..We evaluated the associations between reproductive factors, exogenous hormone use, and lung cancer incidence in the Nurses' Health Study...
  6. ncbi request reprint Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances
    Gary M Strauss
    Division of Medical Oncology, Comprehensive Cancer Center of Rhode Island, Rhode Island Hospital, Brown Medical School, 593 Eddy Street, Providence, RI 02903, USA
    Hematol Oncol Clin North Am 19:263-81, vi. 2005
    ..This article discusses methodologic issues relevant to the interpretation of recent studies focusing on adjuvant chemotherapy of lung cancer. It also attempts to conclude where we currently stand in this field...
  7. pmc Differences in clinical trial patient attributes and outcomes according to enrollment setting
    Elizabeth B Lamont
    Dept of Health Care Policy, Harvard Medical School, 180A Longwood Ave, Boston, MA 02115, USA
    J Clin Oncol 28:215-21. 2010
    ..We compared trial patients' attributes and outcomes by these enrollment settings...
  8. doi request reprint Adjuvant Gamma Knife radiosurgery following surgical resection of brain metastases: a 9-year retrospective cohort study
    Steven W Hwang
    Department of Neurosurgery, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    J Neurooncol 98:77-82. 2010
    ..Although limited by the retrospective nature of our study and lack of some clinical measures, patients undergoing GKS to the resection cavity had a trend towards longer median survival...
  9. ncbi request reprint Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference
    Gary M Strauss
    Division of Medical Oncology, Rhode Island Hospital, Brown Medical School, 593 Eddy St, Providence, RI 02903, USA
    Chest 127:1146-51. 2005
    ..The Como Conference was undertaken to consider the need for a change in the existing recommendations against screening...
  10. ncbi request reprint The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality
    Gary M Strauss
    Division of Hematology Oncology, Roger Williams Medical Center, Providence, RI 02908, USA
    J Clin Oncol 20:1973-83. 2002
    ..This report was undertaken to analyze the trial as a closed cohort study, in an effort to identify predictors of lung cancer incidence and mortality, and to determine whether survival or mortality was unbiased...